Table 1 Characteristics and outcome of COVID 19 patients hospitalized in ICU with delayed intubation 7 days after dexamethasone treatment (≥ 7 days) versus other patients admitted in the same ICU
From: Very late intubation in COVID-19 patients: a forgotten prognosis factor?
All patients (n = 556) | HNFO only (n = 152) | Intubation ≤ 1 day after DXM initiation (n = 196) | Intubation 2 to 7 days after DXM initiation (n = 178) | Intubation > 7 days after DXM initiation (n = 30) | p | |
|---|---|---|---|---|---|---|
Patient’s characteristics | ||||||
Age, years | 59 (50–66) | 58 (46–66) | 60 (50–66) | 59 (52–65) | 63 (57–66) | 0.56 |
Gender male, n (%) | 336 (60) | 97 (64) | 110 (56) | 112 (63) | 17 (57) | 0.55 |
SOFA | 4 (3–7) | 3 (2–4) | 7 (4–9) | 5 (3–7) | 5 (3–7) | < 0.01 |
ROX score on day of HFNO onset, min−1 | 4.2 (3.0–6.0) | 6.7 (4.8–8.6) | 3.0 (2.2–4.0) | 4.2 (3.3–5.2) | 6.0 (4.0–7.5) | < 0.01 |
ROX score at intubation, min−1 | 2.2 (2.0–2.7) | NA | 2.2 (2.0–2.8) | 2.3 (2.0–2.8) | 2.0 (2.0–2.1) | 0.45 |
Comorbidities | ||||||
Arterial hypertension, n (%) | 293 (53) | 67 (44) | 107 (55) | 99 (56) | 20 (67) | 0.38 |
Diabetes, n (%) | 209 (38) | 49 (32) | 78 (40) | 72 (40) | 10 (33) | 0.18 |
IMC > 30 kg m−2, n (%) | 291 (52) | 71 (47) | 116 (59) | 89 (50) | 15 (50) | 0.08 |
Biology | ||||||
White blood cells, G L−1 | 8.6 (6.3–11.3) | 8.4 (6.4–10.5) | 9.1 (6.8–11.2) | 8.7 (1.0–11.5) | 8.7 (6.0–11.8) | 0.757 |
D-dimers, ng mL−1 | 1.4 (1.0–2.5) | 1.5 (0.9–2.8) | 1.2 (0.8–2.6) | 1.6 (0.9–2.4) | 1.4 (1.0–2.1) | 0.93 |
Adjunctive therapies | ||||||
Noninvasive ventilation, n (%) | 120 (22) | 24 (16) | 45 (23) | 43 (24) | 8 (27) | 0.66 |
Awake prone positioning, n (%) | 154 (27) | 71 (50) | 18 (9) | 53 (30) | 12 (40) | < 0.01 |
Tocilizumab, n (%) | 66 (12) | 33 (22) | 5 (3) | 19 (11) | 9 (30) | < 0.01 |
Outcome | ||||||
ICU mortality, n (%) | 219 (39) | 0 (0) | 105 (54) | 88 (49) | 26 (87) | < 0.01 |